Most Read News

Most of the IPO proceeds will be used for deleveraging, allowing for better margins and financial flexibility.

Here are some of the stocks that may see significant price movement today.

The company also said that its board has recommended a final dividend of ₹1.5 per equity share for the FY25.

Headline CPI drops. There’s more to the story as core CPI remains elevated. Will RBI continue its accommodative stance as widely expected?

EBITDA increased 20.3% to ₹191.7 crore in the March 2025 quarter from ₹159.4 crore a year ago.

Nearly 66% of full year hybrid fund flows in FY25 came in the first half of the financial year

The contract is for executing KAVACH, an indigenous train collision avoidance system, in 778 route kilometers in the Bengaluru and Mysuru divisions.

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

The issue may be done through public offers or private placements. This subject to market conditions, and regulatory approvals, stated the public lender.